Newsroom | 4928 results
Sorted by: Latest
-
Smart Meter Opinion Editorial: Remote Patient Monitoring Works. UnitedHealthcare’s 2026 Rollback Ignores the Evidence, and Patients Will Pay the Price.
TAMPA, Fla.--(BUSINESS WIRE)--The following is an opinion editorial provided by Casey Pittock, CEO, Smart Meter: UnitedHealthcare’s decision to sharply limit remote patient monitoring (RPM) reimbursement beginning January 1, 2026, to heart failure and hypertensive disorders of pregnancy, is a disservice to clinicians, patients, and the healthcare system at large. It contradicts federal momentum to modernize chronic care and misrepresents the weight of current evidence on RPM’s clinical value fo...
-
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 202...
-
Klick Health triunfa en el festival El Ojo de Iberoamérica
BUENOS AIRES Y SAN PABLO--(BUSINESS WIRE)--Klick Health recibió 12 galardones este año en el festival El Ojo de Iberoamérica en Buenos Aires, incluido el Gran Premio a la Innovación y seis premios de oro. Dos campañas de Klick, además, clasificaron entre las "Mejores ideas de América". “Este reconocimiento de parte de El Ojo es un testimonio increíble de nuestros equipos globales”, afirmó Rich Levy, CCO. “La pasión, el talento y el empuje incansable siguen impulsando nuestro ritmo de crecimient...
-
Klick Health ganha grande destaque no Festival El Ojo de Iberoamérica
BUENOS AIRES E SÃO PAULO--(BUSINESS WIRE)--A Klick Health ganhou 12 prêmios no Festival El Ojo de Iberoamérica deste ano, em Buenos Aires, incluindo o Grande Prêmio de Inovação e seis prêmios Gold. Duas campanhas da Klick também foram reconhecidas na lista das "Melhores Ideias da América" do festival. "Este reconhecimento do El Ojo é uma prova do trabalho incrível de nossas equipes internacionais", disse Rich Levy, CCO. "A paixão, a capacidade e a dedicação incansável delas continuam impulsiona...
-
Klick Health Wins Big at El Ojo de Iberoamérica Festival
BUENOS AIRES & SÃO PAULO--(BUSINESS WIRE)--Klick Health picked up 12 awards at this year’s El Ojo de Iberoamérica Festival in Buenos Aires, including the Innovation Grand Prix and six Gold. Two Klick campaigns also ranked in the festival’s ‘America’s Best Ideas.’ “This recognition from El Ojo is an incredible testament to our global teams,” said CCO Rich Levy. “Their passion, craft, and relentless drive continue to fuel our record-breaking momentum across the region, and it’s inspiring to see t...
-
How Elevance Health is Evolving the Healthcare Consumer Experience Through Improved Personalization and Higher Touch Service
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health is making healthcare more intuitive and personalized by using technology to simplify access and build trust among health plan members....
-
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts. During the event, Insulet’s executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automa...
-
ABIONYX Pharma et SEBIA annoncent un partenariat stratégique exclusif mondial pour transformer le diagnostic du sepsis
TOULOUSE, France & FULLERTON, Californie & LISSES, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société de biotechnologie de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes basées sur la seule apolipoprotéine apoA- I recombinante au monde, et SEBIA, acteur mondial du diagnostic biologique spécialisé, annoncent aujourd’hui un partenariat stratégique exclusif mondial dans le sepsis. De nouveaux tests de...
-
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
TOULOUSE, France & FULLERTON, Calif. & LISSES, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, and SEBIA, a global player in specialized biological diagnostics, today announced an exclusive global strategic partnership in sepsis. New tests for early diagnosis and monitoring of sepsis treatme...
-
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...